
-
Sarepta Therapeutics NasdaqGS:SRPT Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients with Duchenne with a confirmed mutation in the Duchenne gene. The company is also developing SRP-9003, a limb-girdle muscular dystrophies gene therapy program. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Catalent Maryland, Inc.; Nationwide Children's Hospital; Dyno Therapeutics; Hansa Biopharma; Duke University; and Genethon. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.
Location: 215 First Street, Cambridge, MA, 02142, United States | Website: https://www.sarepta.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
4.628B
Cash
522.8M
Avg Qtr Burn
-136.8M
Short % of Float
9.40%
Insider Ownership
4.44%
Institutional Own.
90.37%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ELEVIDYS (SRP-9001) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
EXONDYS 51 (eteplirsen) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
ELEVIDYS (SRP-9001) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
AMONDYS 45 (casimersen) (SRP-4045) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
VYONDYS 53 (golodirsen) Details Duchenne muscular dystrophy | Approved Quarterly sales | |
BLA Submission | ||
ELEVIDYS (SRP-9001) Details Duchenne muscular dystrophy | Phase 3 Update | |
SRP-5051 (vesleteplirsen) Details Duchenne muscular dystrophy | Phase 2 Update | |
Phase 1 Data readout | ||
SRP-6004 Details Dysferlinopathy, Limb-Girdle Muscular Dystrophy | Phase 1 Update | |
Phase 1 Initiation |